UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

October 18, 2007


Date of Report (Date of earliest event reported)

 

NPS PHARMACEUTICALS, INC.


(Exact name of registrant as specified in its charter)


Delaware

 

0-23272

 

87-0439579


 


 


(State or other jurisdiction of incorporation)

 

(Commission File Number)

 

(I.R.S. Employer Identification Number)


550 Hills Drive, 3rd Floor

Bedminster, NJ 07921


(Address of principal executive offices)

 

(908) 450-5300


(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

o

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

o

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

o

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))




Section 8 — Other Events

Item 8.01 Other Events.

On October 18, 2007, NPS Pharmaceuticals, Inc. issued a press release announcing the expiration and final results of its cash tender offer for any and all of its outstanding 3.0% convertible notes due 2008. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Section 9 — Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits.

 

(c) Exhibits

 

 

99.1

Press Release issued by NPS Pharmaceuticals, Inc. on October 18, 2007 relating to the expiration and final results of the tender offer.


SIGNATURES

          Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 18, 2007

NPS PHARMACEUTICALS, INC.

 

 

 

 

 

 

By:

/s/ Gerard J. Michel

 

 


 

 

Name:  Gerard J. Michel

 

 

Title:    Chief Financial Officer


EXHIBIT INDEX

Exhibit No.

 

Description


 


99.1

 

Press Release issued by NPS Pharmaceuticals, Inc. on October 18, 2007 relating to the expiration and final results of the tender offer.